Hua Han Bio-Pharmaceutical Holdings Ltd ($587) - buy or sell? Stock discussion, ideas, forum

Hua Han Bio-Pharmaceutical Holdings Ltd

Industry: Pharmaceuticals

Ticker	Exchange	ISIN	Name
$587	HKEx Main Board	KYG4638Y1008	Code: 587

Recent news

TAI Ping Carpet International Ltd revenue jumped on 34.8% while EBITDA Margin decreased on 2.8 pp from 9.9% to 7.1%

Vision Fame International Holding Ltd revenue growth accelerated from 2.3% in FY2019 to 405% in FY2020

Kantone Holdings Ltd reports 13.0% EBITDA growth in 2020 and 0.61 pp EBITDA Margin growth from 5.7% to 6.3%

Heng Tai Consumables Group Ltd revenue dropped on 35.5% and EBITDA Margin dropped on 19.0 pp from -27.6% to -46.6%

Yat Sing Holdings Ltd revenue decreased on 8.4% and EBITDA Margin decreased on 2.2 pp from -1.7% to -3.9%

Art Textile Technology International Co Ltd Net Debt / EBITDA surged on 82.8x from 3.9x to 86.8x in 2020 while Revenue dropped on 24.7%

China Zenith Chemical Group Ltd revenue dropped on 39.8% while EBITDA Margin surged on 93.4 pp from -149% to -55.4%

Odella Leather Holdings Ltd revenue returned to growth in FY2020: increased 60.4% vs. 48.6% decline a year earliner

New World Development Co Ltd Net Income dropped on 85.3% and Revenue dropped on 23.1%

NWS Holdings Ltd reports 80.3% Net Income decline in 2020 and 3.4% Revenue decline

Twit about 587 stock

Share your investment idea or question on Hua Han Bio-Pharmaceutical Holdings Ltd stock:

Latest twits on Hua Han Bio-Pharmaceutical Holdings Ltd (587)

No twits yet. Be the first to post!

Have a question about 587? Ask and other investors will be eager to help you.

Have an idea about 587? Share it with other investors.

Hua Han Bio-Pharmaceutical Holdings Ltd news

30/09/2015 Hua Han Bio-Pharmaceutical Holdings Ltd reports 422% CAPEX growth while 2.1% Revenue decline

Hua Han Bio-Pharmaceutical Holdings Ltd stock price chart

Hua Han Bio-Pharmaceutical Holdings Ltd financials

mln. HKD	FY2010	FY2011	FY2012

Revenue	808.6	1,157	1,312
EBITDA	383.2	380.7	795.1
Net income	265.3	441.8	657.2
CAPEX	4.172	43.903	11.779
Debt	55.881	33.222	31.853
Cash	1,407	1,457	2,095

Hua Han Bio-Pharmaceutical Holdings Ltd news

30/09/2015 Hua Han Bio-Pharmaceutical Holdings Ltd reports 422% CAPEX growth while 2.1% Revenue decline

About Hua Han Bio-Pharmaceutical Holdings Ltd

Hua Han Bio-Pharmaceutical Holdings Limited, through its subsidiaries, researches, develops, manufactures, and sells Chinese herbal pharmaceutical products primarily for women and the elderly under its Yeosure brand name. The Company also researches, develops, manufactures, and sells naturally-sourced anti-tumor medicines and western pharmaceutical products.